Michael P. Heldebrant

1.8k total citations · 1 hit paper
10 papers, 1.4k citations indexed

About

Michael P. Heldebrant is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Michael P. Heldebrant has authored 10 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Immunology. Recurrent topics in Michael P. Heldebrant's work include Cell death mechanisms and regulation (4 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). Michael P. Heldebrant is often cited by papers focused on Cell death mechanisms and regulation (4 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Biosimilars and Bioanalytical Methods (2 papers). Michael P. Heldebrant collaborates with scholars based in United States and Canada. Michael P. Heldebrant's co-authors include Scott H. Kaufmann, Charles L. Loprinzi, Stephan D. Thomé, Daniel J. Sargent, S. Stephen, Daniel G. Haller, Guido Francini, Richard M. Goldberg, Lois E. Shepherd and Wei Chen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Michael P. Heldebrant

10 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?

2004 756 citations Sharlene Gill, Charles L. Loprinzi et al. Journal of Clinical Oncology profile →

Peers

Michael P. Heldebrant

ONCOL

MB

PFM

SURGE

IMMUN

Susan Bakke United States

Katsuhide Yoshidome Japan

Chee Wee Ong Singapore

Do-Sun Byun United States

Yoshinori Nio Japan

Takashi Kobunai Japan

Stephan Gysin United States

Yuji Basaki Japan

Parham Minoo Canada

Seon Ae Roh South Korea

Susan Bakke United States

Michael P. Heldebrant

711 ×0.9

ONCOL

816 ×1.4

MB

134 ×0.4

PFM

142 ×0.7

SURGE

123 ×0.8

IMMUN

Citations per year, relative to Michael P. Heldebrant Michael P. Heldebrant (= 1×) peers Susan Bakke

Countries citing papers authored by Michael P. Heldebrant

Since Specialization

Citations

This map shows the geographic impact of Michael P. Heldebrant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Heldebrant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Heldebrant more than expected).

Fields of papers citing papers by Michael P. Heldebrant

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Heldebrant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Heldebrant. The network helps show where Michael P. Heldebrant may publish in the future.

Co-authorship network of co-authors of Michael P. Heldebrant

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Heldebrant. A scholar is included among the top collaborators of Michael P. Heldebrant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Heldebrant. Michael P. Heldebrant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Meng, Xue, Michael P. Heldebrant, Karen S. Flatten, et al.. (2009). Protein Kinase Cβ Modulates Ligand-induced Cell Surface Death Receptor Accumulation. Journal of Biological Chemistry. 285(2). 888–902. 15 indexed citations

2.

Gomez, Timothy S., Michael J. Hamann, Doris N. Savoy, et al.. (2005). Dynamin 2 regulates T cell activation by controlling actin polymerization at the immunological synapse. Nature Immunology. 6(3). 261–270. 131 indexed citations

3.

Mesa, Ruben A., David A. Loegering, Heather L. Powell, et al.. (2005). Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood. 106(1). 318–327. 96 indexed citations

4.

Gill, Sharlene, Charles L. Loprinzi, Daniel J. Sargent, et al.. (2004). Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. Journal of Clinical Oncology. 22(10). 1797–1806. 756 indexed citations breakdown →

5.

Kalli, Kimberly R., Myles C. Cabot, Michael P. Heldebrant, et al.. (2003). Heterogeneous Role of Caspase-8 in Fenretinide-Induced Apoptosis in Epithelial Ovarian Carcinoma Cell Lines. Molecular Pharmacology. 64(6). 1434–1443. 21 indexed citations

6.

Trushina, Eugenia, Michael P. Heldebrant, Carmen Pérez-Terzic, et al.. (2003). Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proceedings of the National Academy of Sciences. 100(21). 12171–12176. 74 indexed citations

7.

Meng, Xue, Michael P. Heldebrant, & Scott H. Kaufmann. (2002). Phorbol 12-myristate 13-Acetate Inhibits Death Receptor-mediated Apoptosis in Jurkat Cells by Disrupting Recruitment of Fas-associated Polypeptide with Death Domain. Journal of Biological Chemistry. 277(5). 3776–3783. 74 indexed citations

8.

Thomé, Stephan D., Charles L. Loprinzi, & Michael P. Heldebrant. (2002). Determination of Potential Adjuvant Systemic Therapy Benefits for Patients With Resected Cutaneous Melanomas. Mayo Clinic Proceedings. 77(9). 913–917. 8 indexed citations

9.

Thomé, Stephan D., Charles L. Loprinzi, & Michael P. Heldebrant. (2002). Determination of Potential Adjuvant Systemic Therapy Benefits for Patients With Resected Cutaneous Melanomas. Mayo Clinic Proceedings. 77(9). 913–917. 4 indexed citations

10.

Heldebrant, Michael P., et al.. (2002). Synthetic Smac/DIABLO Peptides Enhance the Effects of Chemotherapeutic Agents by Binding XIAP and cIAP1 in Situ. Journal of Biological Chemistry. 277(46). 44236–44243. 211 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact